Paper - WANFANG MED ONLINE

You Position: Home > Paper

Current status of immunotherapy for pancreatic cancer

( views:14, downloads:0 )

Author:: No author available

Journal Title:: World Chinese Journal of Digestology

Issue:: 20

DOI:: 10.11569/wcjd.v29.i20.1151

Key Word:: 胰腺癌;免疫治疗;免疫检查点抑制剂;肿瘤疫苗;过继细胞疗法;联合免疫治疗

Abstract：胰腺癌是一种临床预后极差的消化道恶性肿瘤,根治性手术是胰腺癌患者首选治疗方案,但大多数患者确诊时已无根治性手术治疗机会.目前,已开展多项以免疫检查点抑制剂、肿瘤疫苗、过继细胞疗法等手段为主的胰腺癌免疫治疗研究,有望成为胰腺癌治疗的新策略,最终达到提高胰腺癌患者整体预后的目的.本文简要概括胰腺癌免疫治疗研究现状,并分析胰腺癌免疫治疗研究的未来趋势.

Reference

[1]Li Jian,Li Wenwen,Huang Kejia,etc.Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward[J].2018,11(1).
[2]Robert J, Torphy,Yuwen, Zhu,Richard D, Schulick.Immunotherapy for pancreatic cancer: Barriers and breakthroughs.[J].2018,2(4).
[3]Iwai Y,Ishida M,Tanaka Y,etc.Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.[J].2002,99(19).
[4]Synne Wedén,Marianne Klemp,Ivar P. Gladhaug,etc.Long‐term follow‐up of patients with resected pancreatic cancer following vaccination against mutant K‐ras[J].2011,128(5).
[5]Zhou, Ting,Damsky, William,Weizman, Orr-El,etc.IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy[J].2020,583(Jul.23 TN.7817).
[6]Chung, V.,Kos, F. J.,Hardwick, N.,etc.Evaluation of safety and efficacy of p53MVA vaccine combined with pembrolizumab in patients with advanced solid cancers[J].2019,21(3).
[7]Leinwand Joshua,Miller George.Regulation and modulation of antitumor immunity in pancreatic cancer[J].2020,21(10).
[8]Buscail, Louis,Bournet, Barbara,Cordelier, Pierre.Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer[J].2020,17(3).
[9].Stereotatic radiotherapy in metastatic non-small cell lung cancer: Combining immunotherapy and radiotherapy with a focus on liver metastases[J].2020,142.
[10]Anwar, Muhammad Yasir,Williams, Grant R.,Paluri, Ravi K..CAR T Cell Therapy in Pancreaticobiliary Cancers: a Focused Review of Clinical Data[J].2021,52(1).
[11]Soltek,S.,Umansky,V.,Link,J.,etc.Low-dose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer[J].2013,133(1).
[12]Gansukh B,Abou Alfa GK,Capanu M,etc.Targeting mutated K-ras in pancreatic adenocarcinoma using an adjuvant vaccine.[J].2011,34(3).
[13]Larson, Steven M.,Carrasquillo, Jorge A.,Cheung, Nai-Kong V.,etc.Radioimmunotherapy of human tumours[J].2015,15(6).
[14]Weiss Glen J.,Blaydorn Lisa,Beck Julia,etc.Correction to: Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma[J].2019,37(4).
[15]Conroy, T.,Hammel, P.,Hebbar, M.,etc.FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer[J].2018,379(25).
[16]Rosenberg Steven A.,Restifo Nicholas P.,Yang James C.,etc.Adoptive cell transfer: a clinical path to effective cancer immunotherapy[J].2008,8(4).
[17]Nisha Anjali Mohindra,Sheetal Mehta Kircher,Halla Sayed Nimeiri,etc.Results of the phase Ib study of ipilimumab and gemcitabine for advanced pancreas cancer.[J].2019,33(15_suppl).
[18]Raffit, Hassan,Wolfgang, Ebel,Eric L, Routhier,etc.Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin.[J].2007,7.
[19]Berraondo, Pedro,Sanmamed, Miguel F.,Ochoa, Maria C.,etc.Cytokines in clinical cancer immunotherapy[J].2019,120(1).
[20]Hyunjin Park,Yangkyu Lee,Hyejung Lee.The prognostic significance of cancer-associated fibroblasts in pancreatic ductal adenocarcinoma[J].2017,39(10).
[21]Glen J. Weiss,Lisa Blaydorn,Julia Beck,etc.Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma[J].2018,36(1).
[22]Cohn, Allen,Morse, Michael A.,O'Neil, Bert,etc.Whole Recombinant Saccharomyces cerevisiae Yeast Expressing Ras Mutations as Treatment for Patients With Solid Tumors Bearing Ras Mutations: Results From a Phase 1 Trial[J].2018,41(3).
[23]Eric Lutz,Charles J. Yeo,Keith D. Lillemoe,etc.A Lethally Irradiated Allogeneic Granulocyte-Macrophage Colony Stimulating Factor-Secreting Tumor Vaccine for Pancreatic Adenocarcinoma: A Phase II Trial of Safety, Efficacy,and Immune Activation[J].2011,253(2).
[24].Pancreatic cancer[J].2020,395(10242).
[25]O'Reilly, Eileen M.,Oh, Do-Youn,Dhani, Neesha,etc.Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial[J].2019,5(10).
[26]Aglietta,M.,Barone,C.,Sawyer,M.B.,etc.A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer[J].2014,25(9).
[27]Brower, Vicki.Checkpoint Blockade Immunotherapy for Cancer Comes of Age[J].2015,107(3).
[28]Kamath Suneel D.,Kalyan Aparna,Kircher Sheetal,etc.Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: A Phase Ib Study[J].2020,25(5).
[29]Marianne K. Gjertsen,Trond Buanes,Arne R. Rosseland,etc.Intradermal ras peptide vaccination with granulocyte‐macrophage colony‐stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma[J].2001,92(3).
[30]Melief, Cornelis J. M.,van Hall, Thorbald,Arens, Ramon,etc.Therapeutic cancer vaccines[J].2015,125(9).
[31]Abul Azad,Su Yin Lim,Zenobia D'Costa,etc.PD‐L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy[J].2017,9(2).
[32]Hamilton,M.,Behrens,R.,Marincola,F.,etc.Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers[J].2008,57(9).
[33]Jin Jing,Zhao Qijie.Engineering nanoparticles to reprogram radiotherapy and immunotherapy: recent advances and future challenges[J].2020,18(1).
[34]Le,D.T.,Lutz,E.,Uram,J.N.,etc.Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer[J].2013,36(7).
[35]Mehrotra Shikhar,Britten Carolyn D.,Chin Steve,etc.Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer[J].2017,10(1).
[36].Synergizing systemic responses by combining immunotherapy with radiotherapy in metastatic non-small cell lung cancer: The potential of the abscopal effect[J].2020,142.
[37]Ho Won Jin,Jaffee Elizabeth M.,Zheng Lei.The tumour microenvironment in pancreatic cancer — clinical challenges and opportunities[J].2020,17(9).
[38]Jiang, Ni,Qiao, Guoliang,Wang, Xiaoli,etc.Dendritic Cell/Cytokine-Induced Killer Cell Immunotherapy Combined with S-1 in Patients with Advanced Pancreatic Cancer: A Prospective Study[J].2017,23(17).
[39]Levy C,Rosenberg SA,Turner K,etc.Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma.[J].2010,33(8).
[40]Landman, Allison,Ham, Laura Feet,Stuckey, Daniel.Working together to reduce the burden of pancreatic cancer[J].2020,21(3).
[41]Tsujikawa, Takahiro,Crocenzi, Todd,Durham, Jennifer N.,etc.Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic[J].2020,26(14).
[42]Philippou, Yiannis,Sjoberg, Hanna T.,Murphy, Emma,etc.Impacts of combining anti-PD-L1 immunotherapy and radiotherapy on the tumour immune microenvironment in a murine prostate cancer model[J].2020,123(7).
[43]Bear, Adham S.,Vonderheide, Robert H.,O'Hara, Mark H..Challenges and Opportunities for Pancreatic Cancer Immunotherapy[J].2020,38(6).